|Bid||6.15 x 100|
|Ask||12.00 x 200|
|Day's Range||10.35 - 11.00|
|52 Week Range||4.15 - 11.00|
|PE Ratio (TTM)||-3.80|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||20.50|
Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017, at 10:00 a.m.
Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration has granted a Breakthrough Therapy Designation to entrectinib “for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or who have no acceptable ...
Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced the closing of its previously announced underwritten public offering of 14.375 million shares of its common stock at a price to the public of $6.15 per share, which includes 1.875 million additional shares of common stock issued upon the exercise in full of the underwriters’ option to purchase additional ...